Trials / Completed
CompletedNCT01400828
Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis
Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg After 14-day Oral Administration in Patients With Seasonal Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 239 (actual)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- All
- Age
- 12 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bilastine | 20 mg (encapsulated) tablets QD/14 days |
| DRUG | Desloratadine | 5 mg (encapsulated) tablets QD/14 days |
| DRUG | Placebo | (encapsulated) Tablets QD/14 days |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2013-06-01
- Completion
- 2014-05-01
- First posted
- 2011-07-22
- Last updated
- 2014-07-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01400828. Inclusion in this directory is not an endorsement.